The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients by Van Duyne, Rachel et al.
Van Duyne et al. AIDS Research and Therapy 2010, 7:21
http://www.aidsrestherapy.com/content/7/1/21
Open Access RESEARCH
© 2010 Van Duyne et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Research The identification of unique serum proteins of 
HIV-1 latently infected long-term non-progressor 
patients
Rachel Van Duyne1,2, Irene Guendel2, Kylene Kehn-Hall2, Rebecca Easley2, Zachary Klase3, Chenglong Liu4, 
Mary Young4 and Fatah Kashanchi*2,5
Abstract
Background: The search for disease biomarkers within human peripheral fluids has become a favorable approach to 
preventative therapeutics throughout the past few years. The comparison of normal versus disease states can identify 
an overexpression or a suppression of critical proteins where illness has directly altered a patient's cellular homeostasis. 
In particular, the analysis of HIV-1 infected serum is an attractive medium with which to identify altered protein 
expression due to the ease and non-invasive methods of collecting samples as well as the corresponding insight into 
the in vivo interaction of the virus with infected cells/tissue. The utilization of proteomic techniques to globally identify 
differentially expressed serum proteins in response to HIV-1 infection is a significant undertaking that is complicated 
due to the innate protein profile of human serum.
Results: Here, the depletion of 12 of the most abundant serum proteins, followed by two-dimensional gel 
electrophoresis coupled with identification of these proteins using matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry, has allowed for the identification of differentially expressed, low abundant 
serum proteins. We have analyzed and compared serum samples from HIV-1 infected subjects who are being treated 
using highly active antiretroviral therapy (HAART) to those who are latently infected but have not progressed to AIDS 
despite the absence of treatment, i.e. long term non-progressors (LTNPs). Here we have identified unique serum 
proteins that are differentially expressed in LTNP HIV-1 patients and may contribute to the ability of these patients to 
combat HIV-1 infection in the absence of HAART. We focused on the cdk4/6 cell cycle inhibitor p16INK4A and found that 
the treatment of HIV-1 latently infected cell lines with p16INK4A decreases viral production despite it not being 
expressed endogenously in these cells.
Conclusions: Identification of these unique proteins may serve as an indication of altered viral states in response to 
infection as well as a natural phenotypic variability in response to HIV-1 infection in a given population.
Background
Human serum is derived from the liquid plasma compo-
nent of the blood with the fibrinogens, or clotting factors,
removed and is composed of small molecules such as
salts, lipids, amino acids, sugars and approximately 60-80
mg of proteins/mL [1]. Serum is a readily obtainable
peripheral bodily fluid from which the protein profile
directly reflects the normal or disease state of the organ-
ism [2-4]. Serum is a complex mixture of "classical" and
"non-classical" proteins. Classical serum proteins are
involved in a number of processes including proteolysis,
inhibition, binding, transport, coagulation, and immune
response and are often secreted from the liver, through
the intestines, and into the bloodstream [5]. "Non-classi-
cal" proteins are proteins that are not directly tied to any
known function within the serum and often originate
from cellular leakage or shedding, and may utilize the
bloodstream for transportation [5]. It is generally
accepted that most of the significant changes in the
serum will be found in these low abundant non-classical
proteins, due to the hypothesis that the presence of these
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proteins should reflect changes in the diseased tissue.
Indeed, serum commonly contains upwards of 10,000 dif-
ferent proteins at any given time that are being actively
produced and secreted by all cells and tissues, therefore,
the proteomic profile of serum can give insight into the
systemic reaction to a disease state and can serve as a
pool of differentially expressed proteins [2,6-13].
Recently, the interest in characterizing the human serum
proteome has increased due to the determination of dis-
ease biomarkers for early detection, diagnosis, and drug
targeting; however, due to the extensive dynamic range of
protein concentration within the serum, the identifica-
tion of low abundance proteins suitable for biomarker
determination is often masked. The 22 highly abundant
proteins contained within serum constitute approxi-
mately 99% of the total serum proteins, including albu-
min, IgG, transferrin, haptoglobin, fibrinogen, etc. and
interfere with the identification of low abundance pro-
teins in the ng/mL concentration range. The presence of
these highly abundant proteins necessitates the prefrac-
tionation of serum samples prior to analysis for low abun-
dant proteins. Due to the dynamic insight the analysis of
the serum proteome can relate to a disease state, of par-
ticular interest is the identification of low abundant pro-
teins that change in expression or abundance in response
to a disease state. These low abundant proteins could
potentially arise as an early diagnostic for a disease state,
or a therapeutic target.
Serum proteomics has emerged as an integral bio-
marker identification and diagnostic tool, especially for
infectious diseases and oncology. Recently, novel serum
biomarkers have been identified for liver fibrosis in hepa-
titis C virus (HCV) infected patients as well as unique
protein signatures in SARS coronavirus infections, and
infant hepatitis syndrome induced by human cytomega-
lovirus (HCMV) infection [14-16]. Characterization of
the serum protein profile of these viral states helps pro-
vide insight into the expression changes associated with
viral infection. In particular, HIV-1 infection, even at the
acute phase, results in dramatic changes in both cellular
and viral protein expression levels. As the HIV-1 viral tro-
pism consists primarily of CD4+ T-cells, macrophages,
and dendritic cells, the resulting protein changes can be
seen systemically as infected cells travel throughout the
body. Additionally, the nature of this viral infection sup-
ports the secretion of altered proteins into the blood and
subsequently the serum due to the propensity of the virus
to stimulate apoptosis of infected cells, therefore empty-
ing cellular contents into the serum. These characteristics
of HIV-1 infection suggest that the analysis of the serum
of infected patients is an appropriate reflection of a
patients' altered protein expression state.
Due to innate genetic and phenotypic differences in the
human population, significant variability exists in the sus-
ceptibility to HIV-1 infection. Amongst this diversity
includes the well-studied CCR5Δ32 inherited mutation,
which prevents the binding of R5-tropic HIV-1 strains to
the CCR5 chemokine receptor on the surface of CD4+ T-
cells, therefore preventing entry of the virus [17]. Addi-
tionally, some individuals can be infected with HIV-1,
however will not progress to AIDS even in the absence of
therapy. These Long Term Non-Progressors (LTNPs) are
often characterized as being infected with HIV-1 but are
also disease free and sustain a normal CD4 T-cell count
and a low viral load. Over the past 20 years, multiple
studies have been aimed at determining the reason that
these individuals are able to resist disease progression.
There are studies that suggest that the virus infecting
these cells could be deficient in some way, for example,
Nef deficient viruses and Vpr R77Q mutations are associ-
ated with LTNPs [18-22]. A number of host factors have
also been identified that may contribute to the observed
resistance. LTNPs have a higher prevalence of the
CCR5Δ32 allele [17,23-25]. In addition, the presence of
certain HLA genes including HLA-B27, HLA-B*5701,
HLA-B*5401, and HLA-B*1507 have been linked to
LTNP [26-28] however, the identified alterations do not
account for all cases of LTNP. Therefore, the search for
protective host factors is still an area of active investiga-
tion in hopes of obtaining information that could be of
therapeutic value.
Here, we describe the detection of unique, low abun-
dant serum proteins in latently infected HIV-1 LTNPs as
com pared t o serum from pa tien ts under going HAAR T
treatment, and those not infected with HIV-1. We
attempted to characterize the underlying differences in
LTNPs that contribute to the ability of these patients to
combat HIV-1 infections. We have depleted 12 of the
most highly abundant serum proteins from three sets of
serum samples (uninfected, infected on HAART, LTNP)
and identified differentially expressed proteins across the
samples. In particular, we focus on the identified cellular
protein p16INK4A which is found preferentially in LTNP
patient serum samples, but is not present in patients
undergoing HAART treatment. In vitro viral assays and
viability studies confirm the loss of viral replication upon
p16INK4A treatment in latently infected cell lines and the
non-toxic effect of the same treatment in corresponding
uninfected cell lines.
Results
Depletion of the 12 highly abundant serum proteins allows 
for the identification of low abundant proteins
To begin the identification of unique serum proteins, we
obtained 18 subject serum samples: six LTNP, six HIV-1
infected subjects receiving HAART therapy (HAART)
and six HIV-uninfected individuals through the Wash-
ington DC site of the Women's Interagency HIV StudyVan Duyne et al. AIDS Research and Therapy 2010, 7:21
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(WIHS) Georgetown site (Table 1). WIHS is an NIH mul-
ticenter study of the natural history of HIV-1 infection in
women [29]. LTNPs are defined by WIHS as being HIV-1
infected, but disease free for at least five years, having a
CD4 count of greater than 500 at all visits and having no
history of anti-retroviral therapy. The difficulty associ-
ated with analyzing serum is the presence of a high abun-
dance of proteins which mask potential low abundance
biomarkers. To overcome this obstacle, we utilized the
ProteomeLab IgY serum depletion kit which removes 12
of the most abundant proteins in serum: albumin, IgG,
transferrin, fibrinogen, IgA, α2-macroglobulin, IgM, α1-
antitrypsin, haptoglobin, α1-acid glycoprotein, apolipo-
protein A-I, and apolipoprotein A-II. As can be observed
in Figure 1A, whole serum (lanes 2, 3) contains many pro-
teins and is too complex to allow for confident identifica-
tion of specific proteins. However, when the high
abundant proteins (Figure 1, lanes 8, 9) are removed,
l o w e r  a b u n d a n t  p r o t e i n s  t h a t  w e r e  o r i g i n a l l y  m a s k e d
(Figure 1, lanes 4, 5) are able to be analyzed. Along these
lines, we found the ProteomeLab IgY serum depletion kit
to be the most appropriate and reproducible manner in
which to fractionate our serum samples into high and low
abundant fractions. We applied this depletion strategy to
pooled patient samples, combining equal volumes of
whole serum from each of the six patients per sample set
(LTNP, HAART, and Negative), which were subsequently
depleted into low and high abundance fractions. We
began the analysis with pooled samples to assist in the
identification of HIV-1 infection specific protein identifi-
cation as opposed to identifying individual patient and
serum variability. These pooled samples were separated
based on 1D SDS-PAGE (Figure 1B) and comparisons
between LTNP, HAART, and Negative low abundant
samples were carried out via in-gel trypsin digestion,
peptide elution and desalting, followed by MALDI-TOF
mass spectrometry as indicated by numbered arrows
marking excised bands. The subsequent protein identifi-
cations served as a preliminary indication of differentially
expressed proteins between the three patient types.
These observations, as summarized in Table 2, provide an
insight into the relevance of proteins identified in the
context of the state of HIV-1 infection. Of particular
interest in Table 2 is the identification of HIV-1 enhancer
binding protein 1, (HIVEP1), Ribonuclease III, and het-
erochromatin protein 1 binding protein in the low abun-
dance LTNP fraction. HIVEP1 is a member of the ZAS
family of proteins which bind the promoter and enhancer
regions of both cellular genes and infectious viruses,
including HIV-1. Also known as PRDII-BF1 or MBP-1,
this transcription factor binds to both the NF-κB and the
TAR transactivation response DNA elements on the HIV-
1 LTR in both the presence and absence of HIV-1 Tat
[30,31]. It is not surprising that a transcription factor
such as HIVEP1 would be present during HIV-1 infec-
tion; however, the identification of this protein is not nec-
essarily a marker for a LTNP phenotype. Ribonuclease III,
o r  D r o s h a ,  i s  a  c e l l u l a r  e n z y m e  f o u n d  i n  t h e  n u c l e u s
which serves to cleave double-stranded RNA hairpin
transcripts as a key step in the production of miRNAs in
the RNA interference pathway. Interestingly, heterochro-
matin protein 1, or HP1 is a member of the chromatin
remodeling family of proteins, which can bind histones at
methylated lysine residues and can interact with many
Table 1: Patient samples obtained from the WIHS 
Interagency Cohort.







7 HAART Responder 12.18
8 HAART Responder 12.80
9 HAART Responder 12.23
10 HAART Responder 12.12
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chromatin-associated nonhistone proteins. The HP1
family of proteins has been associated with promoting a
heterochromatic cellular state, where latently HIV-1
infected cells can persist as a transcriptionally silent pro-
virus [32,33]. It may be of interest that an HP1 binding
protein would be present in the serum of an HIV-1
infected patient as HP1, including its subtypes α, β, and γ,
could be involved in the control of various stages of infec-
tion. It is possible that the association of this HP1 binding
protein with varying subtype of HP1 could explain the
differences in patient phenotypes, especially those that
result in an altered susceptibility to viral infection.
2DGE and MALDI-TOF analysis of pooled, depleted serum 
samples identified unique low abundance proteins
Following the initial 1D separation and MALDI-TOF MS
assisted identification, the pooled patient samples were
subjected to 2D-gel electrophoresis (2DGE); isoelectric
focusing (IEF) using IPG strips with a pH 3.0-10.0 range
followed by SDS-PAGE using 4-20% Tris-Glycine Crite-
rion gels. The method of 2D-gel electrophoresis is much
more sensitive than 1D-gel electrophoresis in that it pro-
vides separation of a complex mixture of proteins in two
dimensions, therefore removing the complexity associ-
ated with overlapping proteins, or masking due to post-
translational modifications. 2DGE is a more sensitive
front-end purification approach to the isolation and iden-
tification of individual protein species by mass spectrom-
etry. Figure 2 depicts the LTNP, HAART, and Negative
low abundance fractions in gels "a", "b", and "c", respec-
tively, as well as the LTNP, HAART, and Negative high
abundance fractions in gels "d", "e", and "f", respectively.
Indicated protein spots from all gels were excised based
on a comparison of protein abundance and the presence
of unique spots in a given patient set, were subjected to
in-gel trypsin digestion, and were identified by MALDI-
TOF mass spectrometry. It is important to note that
although gels "d," "e," and "f" contain the majority of the
high abundance proteins, unique small protein spots can
still be visualized on these gels. This indicates that not
only will these high abundant proteins mask proteins of
interest; they can also interact with and seclude lower
abundance proteins from being identified. Peak lists from
the collected mass spectra were processed via peptide
mass fingerprinting (PMF) analysis using the Mascot and
ProFound databases, compared, and compiled into a non-
exhaustive list of identified proteins as displayed in Table
3. Of particular interest are those proteins identified from
gel "a" indicating unique low abundance proteins in the
serum of LTNP patients: Tropomyosin 3, protein kinase
3, and cdk4/6 binding protein p16. Tropomyosin interacts
with actin filaments to provide stability and regulates
other actin binding proteins. This family of proteins has
been shown to be cleaved by HIV-1 protease in vitro,
resulting in the dissociation of critical cytoskeletal ele-
ments, which may demonstrate the alteration of muscle
structure in the presence of an HIV-1 infection [34]. Pro-
tein kinase 3, or Protein kinase C (PKC) is a member of
the family of serine/threonine kinases that are integrally
involved in key cellular signaling pathways and can phos-
phorylate a wide variety of substrates. Not surprisingly,
HIV-1 infection alters the PKC phosphorylation pathway
to stimulate TNF-α production by monocytes as well as
other cytokines and growth factors such as IL-6, IL-10,
and MCP-1 [35-39]. PKC has also been shown to be nec-
essary for HIV-1 Tat-mediated transactivation as well as
directly phosphorylating Tat at serine 46 [40,41] and
plays an integral role in the signaling and secretion of
cytokines in response to HIV-1 envelope proteins gp120,
gp160, and gp41 [42,43]. Of particular interest in the low
abundance, LTNP fraction is the presence of the cdk4/
cdk6 binding protein p16, or more specifically, p16INK4A,
a member of the inhibitor of kinase 4/alternative reading
frame (INK4/ARF) family of endogenous cdk (cyclin-
dependent kinase) inhibitors [44]. Dysregulation of the
cell cycle, including the manipulation of cdks and their
associated Cyclins is often a hallmark of cancerous and
infectious phenotypes. Indeed HIV-1 and its associated
proteins have been known to alter the phosphorylation
state and activity of these kinases. P16INK4A inhibits the
phosphorylation of Rb by competitively inhibiting the
association of cdk4/Cyclin D therefore inhibiting the
release of Rb-bound proteins, such as E2F, and the subse-
quent progression into the S phase of the cell cycle
[44,45]. This small molecular weight protein is an attrac-
tive candidate for a secreted, differentially expressed pro-
tein in response to HIV-1 infection.
In addition to these low abundant protein identifica-
tions, the LTNP high abundant samples (gel "d") indicated
the presence of the FGFR1 oncogenic partner and
PCTAIRE protein kinase 3 as well as an anti-HIV-1 gp120
IgG 16 cκ light chain. FGFR1 oncogene partnered with
the fibroblast growth factor receptor 1 (FGFR1) is
thought to be associated with myeloproliferative disor-
ders and as of yet is not associated with any HIV-1 pro-
tein interactions or associated disease phenotypes.
PCTAIRE protein kinase 3, however, is a member of the
serine/threonine family of protein kinases and more spe-
cifically, the cdc2/cdkx subfamily that plays a role in
broad signal transduction pathways. This serine/threo-
nine kinase family member has also been associated with
the essential regulation of cell cycle progression, as well
as transcription and DNA repair [46]. This protein identi-
fication again demonstrates the role that HIV-1 infection
plays in the dysregulation of cellular kinases and specifi-
cally, cell cycle progression.
The HAART responder patient samples (gels "b" and
"e") also contained unique protein candidates: serine/Van Duyne et al. AIDS Research and Therapy 2010, 7:21
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Table 2: Protein Identification of Serum Depleted Samples from 1D SDS-PAGE
Spot # Group Type Protein Name Accession # pI MW (kDa)
2 LTNP Low Human immunodeficiency virus type 1 
enhancer binding protein 1
gi 55662194 8.3 296.68
3 LTNP Low Ribonuclease III (Drosha) gi 20139357 8.5 159.23
4 LTNP Low ADAM metallopeptidase with 
thrombospondin type 1 motif, 18
gi 38649249 9.7 135.12
5 LTNP Low Tax1-binding protein TXBP151 gi 5776545 5.3 86.23
7 LTNP Low Heterochromatin protein 1, binding protein gi 55961949 9.8 57.19
8 LTNP Low Gga-Vhs domain & Beta-Secretase C-terminal 
phosphopeptide
gi 38492866 5.5 17.92
11 LTNP High MHC class I antigen gi 33413287 8.0 10.43
1 HAART Low Coagulation factor V (Proaccelerin, labile 
factor)
gi 56417672 5.7 252.19
6 Uninfected Low Matrix metalloproteinase 2 preprotein gi 11342666 5.3 73.86
9 Uninfected Low Ribosomal protein L27 gi 4506623 10.6 15.78
10 Uninfected Low Ribosomal protein L36a gi 10445223 11.1 12.42
12 Uninfected High P63 protein gi 34304700 7.1 11.39
threonine kinase 33, the Kelch repeat domain containing
protein 11, and the SNW1 protein/APAF1 interacting
protein in the low abundant fraction as well as the pre-B-
cell leukemia homeobox interacting protein 1 in the high
abundant fraction. Of functional interest is the general
serine/threonine kinase 33 as we have already identified
several cellular kinases of the same family. Additionally,
the SNW1 protein is a transcriptional coactivator that
induces the expression of vitamin D, retinoic acid, estro-
gen, and glucocorticoid associated genes. SNW1/SKIP
interacts with HIV-1 Tat through the association with p-
TEFb (cdk9/Cyclin T1) at the TAR RNA complex, stimu-
lating HIV-1 transcription elongation [44]. Interestingly,
some of the protein spots identified the presence of
serum albumin contamination (spots a2, d5, d7, and e2),
which both served as an internal positive control for mass
spectrometry and also indicated that the depletion col-
umns are not completely efficient at removing contami-
nating high abundant proteins.
Validation of MS protein identifications by Western Blot
In order to further confirm the presence of these proteins
in the serum as identified by mass spectrometry, we per-
formed western blots on the same low and high abundant
pooled fractions (Figure 3A). P16INK4A is present in both
the low and high abundant fractions of the pooled LTNPs
(lanes 3, 4) and is also observed in the high abundance
fraction of uninfected patients (Figure 3A, lane 2). Inter-
estingly, this protein is not present in HAART patient
samples at all (Figure 3A, lane 5, 6). The presence of this
protein in serum may be specific to individuals that con-
fer resistance to chronic HIV-1 infection. As p16INK4A is
an inhibitor of cell cycle kinases, in particular cdk4 and
cdk6, the levels of cdk4 in the serum samples was assayed
and was shown to be ubiquitously expressed across all
low and high abundance serum samples (Figure 3A, third
panel from top). Indeed, levels of cdk6 were not detect-
able in any of the patient serum samples as compared to a
293T whole cell extract positive control (data not shown).Van Duyne et al. AIDS Research and Therapy 2010, 7:21
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This implies that the presence of cdk4 in the serum is not
dependent on the presence or absence of p16INK4A and
likewise, p16INK4A does not affect the expression levels of
cdk4 amongst the patient serum samples. The HP1 bind-
ing protein was initially identified in the 1D/mass spec-
trometry analysis in the LTNP low abundance fraction,
therefore the serum levels of both HP1α and HP1γ sub-
units were assayed (Figure 3A). The family of heterochro-
matin-associated proteins exist as three distinct isoforms,
α, β, and γ and all act as regulators of heterochromatin-
mediated transcriptional silencing [47]. HP1α has been
shown to directly interact with DNA methyltransferases
and histone methyltransferases to mediate transcrip-
tional silencing [48,49] and HP1γ, in particular, interacts
with the histone methyltransferase Suv39H1 to initiate a
chromatin-mediated repressive state of the HIV-1 inte-
grated virus [50]. HP1α was shown to be present in the
low abundance fractions of all of the patient phenotypes
whereas HP1γ was shown to be present in both the low
and high abundant fractions across all patient types (Fig-
ure 3A). HP1γ is observed in lower amounts in both the
Negative and HAART high abundance fractions and all
serum samples indicate the presence of a post-transla-
tional modification (i.e. a doublet band) as compared to
the 293T whole cell extract positive control. This indi-
cates that the HP1γ found in serum exists in both a modi-
fied and unmodified form. Interestingly, PCTAIRE was
present in the highest abundance in the uninfected (Neg-
ative), high abundance fraction (Figure 3A, lane 2), how-
ever low levels were also seen in both LTNP and HAART
high abundance fractions (Figure 3A, lane 4, 6). PCTAIRE
was identified initially by mass spectrometry in the high
abundance LTNP sample and can be seen in the high
abundance fractions of all three of the patient types bio-
chemically, however it is present in lower amounts in the
HIV-1 infected patients, indicating that this kinase may
be differentially expressed upon infection though not
necessarily a unique identifier for infection. P16INK4A is
the only protein identified from mass spectrometric anal-
ysis and confirmed biochemically that is specific for the
Figure 1 1D Demonstration of the depletion capabilities of the IgY-12 High Capacity SC Spin Column kit on patient serum. Depletion of pa-
tient serum was performed as indicated by manufacturer's instructions. Low and High abundant fractions were collected for each sample and run on 
a 1D 4-20% Tris-Gycine SDS-PAGE gel. A) Whole serum (lanes 2, 3) was incubated with the column containing antibodies against 12 of the high abun-
dant serum proteins. Low abundant proteins (lanes 4, 5) were collected as the flowthrough, the column was washed (lanes 6, 7) and the high abun-
dant proteins eluted (lanes 8, 9). Briefly the observed high abundant proteins were compared to the known sizes of the expected proteins as indicated. 
B) Equal volumes of serum from each of the six patients within each category (LTNP, HAART, and Negative) were pooled together to create a stock of 
each condition, independent of patient-to-patient variability. Twenty microliters of each stock was subjected to depletion and equal concentration 
of Low and High fraction were run on a 1D gel. Lanes 2, 3 and 4 are the low abundance fractions of the pooled LTNP, HAART, and Negative patients, 
respectively. Lanes 6, 8, and 10 are the high abundance fractions of the pooled LTNP, HAART, and Negative patients, respectively. The indicated arrows 
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Table 3: Protein Identification of Serum Depleted Samples from 2D SDS-PAGE
Spot # Group Type Protein Name Accession # pI MW (kDa) % Coverage
A2 LTNP Low Serum albumin gi 23307793 6.1 69.38 14%
A4 LTNP Low Tropomyosin 3 gi 55665778 4.8 26.26 13%
A6 LTNP Low Protein kinase 3 gi 4226043 6.4 13.48 12%
A7 LTNP Low Cyclin D-dependent kinase 4 and 6-binding protein/
p16
gi 861472 5.7 16.51 24%
B1 HAART Low Serine/Threonine kinase 33 gi 23943882 6.6 57.81 14%
B3 HAART Low Kelch repeat domain containing protein 11 gi 7662260 5.8 65.7 12%
B15 HAART Low SNW1 protein/APAF1 interacting protein gi 40850966 9.9 35.97 21%
C2 Uninfected Low Eukaryotic translation initiation factor 4B gi 49256408 5.5 69.15 10%
C4 Uninfected Low RRBP1 protein gi 38014595 4.9 73.67 13%
D1 LTNP High FGFR1 oncogene partner gi 15080276 4.5 40.9 12%
D5 LTNP High Serum albumin gi 23307793 6.1 69.38 15%
D6 LTNP High Anti-HIV-1 gp120 IgG 16c kappa light chain gi 40647136 7.8 20.67 26%
D7 LTNP High Serum albumin gi 23307793 6.1 69.38 19%
D8 LTNP High PCTAIRE protein kinase 3 gi 55960102 9.1 54.16 18%
E1 HAART High Pre-B-cell leukemia homeobox interacting protein 1 gi 55960102 5.2 72.9 9%
E2 HAART High Serum albumin gi 23307793 6.1 69.38 15%
low abundance LTNP serum samples; although the pro-
tein is also identified in the uninfected and the high abun-
dance LTNP fractions. These results are also interesting
due to the involvement of p16INK4A in alterations of cell
cycle control, additionally, mutations in p16INK4A  are
found in various cancers including pancreatic, lympho-
mas, and sarcomas, contributing to cancer progression
[45]. These findings also indicate a difference in composi-
tion of serum proteins present in HIV-1 infected individ-
uals undergoing HAART treatment versus those that are
naturally non-progressing.
In order to address the concern that the protein signa-
ture of the pooled set of samples for each patient type
may not be an accurate representation of the individual
variability that could be present, we screened the low
abundance fractions of the LTNPs for the presence of
both p16INK4A and cdk4. Results in Figure 3B indicate the
lack of detection of p16INK4A in any of the low abundant
LTNP samples, especially as compared to the pooled
sample "A" (lane 2). In contrast, p16INK4A was detectable
in LTNP patients 1 and 2, as well as in the pooled sample
"D" for the corresponding high abundance fractions
(lanes 2, 3, 4). Due to the nature of the depletion step
based on immuno-affinity, it is not surprising that
p16INK4A is detectable in individual high abundant sam-
ples, as it is probably coupled to a larger, more abundant
protein and was not efficiently depleted. Additionally,
post-depletion, the low abundant fractions for eachVan Duyne et al. AIDS Research and Therapy 2010, 7:21
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patient were very dilute and the protein levels were unde-
tectable by traditional methods. Cdk4 was detectable in
the LTNP low abundant individual samples with variable
abundance, correlating with the data in Figure 3A. Inter-
estingly, cdk4 was not detectable in the LTNP high abun-
dant individual samples, indicating that this protein was
effectively isolated away from the high abundant proteins.
Although through a straight western blot, the levels of
p16INK4A  were undetectable, Figure 3C indicates that
p16INK4A can indeed be immunoprecipitated out of the
individual low abundant LTNP samples and subsequently
detected by western blot. Lanes 1, 2, and 3 represent the
pooled "A" sample and patient samples 2 and 3, respec-
tively. The pooled "A" sample was incubated with α-IgG,
and patient samples 2 and 3 were incubated with α-p16.
These three immunoprecipitations were subjected to
very stringent wash conditions of TNE600 + 0.1% NP-40,
TNE300 + 0.1% NP-40, and TNE50 + 0.1% NP-40 in order
to remove any non-specific proteins. As can be seen in
Figure 3C, lanes 1-3 there is some non-specific p16 bind-
ing to the α-IgG negative control lane, however, the IPs
from the two samples result in much higher percentage of
p16INK4A present, especially in lane 3. As compared to
lanes 4-10, where the salt washes were of less stringency,
there are variable levels of p16INK4A  IPed from each
patient sample. Based on the background levels of
p16INK4A in lane 1, we feel confident in concluding that
the patients 2, 3, 4, and 6 have a detectable level of
p16INK4A only after immunoprecipitation.
RT activity of HIV-1 infected cells decreases in vitro in the 
presence of exogenous p16INK4A
A l t h o u g h  w e  h a v e  i d e n t i f i e d  p 1 6 INK4A  as differentially
present in the serum of HIV-1 infected LTNPs as com-
pared to HAART treated individuals, this may not
directly correlate to viral pathogenesis or functionality of
this protein. In order to gain insight into the reason why
p16INK4A may be present preferentially in the serum of
LTNP patients, we treated latently infected HIV-1 cell
lines (J1.1 and U1) with exogenous purified GST-
p16INK4A Figure 4A depicts an RT assay which measures
the viral reverse transcriptase activity of infected cells
and is an indicator of functional particle production. In
the presence of both 0.1 and 0.5 ug of GST-p16INK4A, J1.1
latently infected T-cells exhibited a decrease in RT activ-
ity (cpm) whereas the higher concentration of GST-
p16INK4A was able to elicit a decrease in RT activity in the
latently infected monocytes, U1, as compared to the GST
treatment alone. This data suggests that the presence of
p16INK4A in serum may result in a decrease in viral repli-
cation, which may help to explain why the presence of
p16INK4A in the serum of LTNPs could correlate with an
overall lack of viral activity.
Treatment of uninfected cells with p16INK4A does not affect 
cellular viability
To detect whether p16INK4A had an effect on normal or
uninfected cells, we performed an MTT assay to screen
for the percentage of cells viable after p16INK4A treatment.
Figure 4B depicts CEM, Jurkat, and H9 uninfected T-cell
lines, as well as the uninfected monocytic U937 cell line
treated with GST as well as GST-p16INK4A. CEM, H9, and
U937 control cells showed no appreciable decrease in cel-
lular viability upon 48 hours of treatment with any of the
four conditions. Interestingly, in the presence of 0.5 ug of
GST-p16INK4A, Jurkat cells exhibit an almost 40%
decrease in cellular viability. We next performed western
blots on whole cell extracts from all four of these unin-
fected cell lines and observed only Jurkat cells exhibiting
an endogenous expression of p16INK4A (Figure 4D, lane 2).
This suggests that the decrease in cellular viability seen in
Jurkat cells (Figure 4B) treated with p16 INK4A can be cor-
related with the expression of exogenous p16INK4A  in
these cells, resulting in an increase in cdk4,6/Cyclin D
inhibition and an increase in apoptosis. Interestingly, no
endogenous levels of p16INK4A are detected in the infected
J1.1 cells.
Cellular Rb levels decrease as a result of the exogenous 
addition of p16INK4A to Jurkat T cells
P16INK4A is a critical member of the Rb tumor-suppressor
pa t h wa y which acts t o arr est the ce ll-cycle a t G1/S by
inhibiting the binding of cdk4/6 to Cyclin D1 and subse-
quently inhibiting the phosphorylation of Rb. In Figure
4C, we investigate the levels of Rb present in Jurkat cells
alone (lane 1) compared to Jurkat cells treated with an
excess of GST or GST-p16INK4A (2.5 μg, lanes 2 and 3).
Interestingly, upon treatment of exogenous GST-
p16INK4A, we observed a decrease in cellular levels of Rb;
indeed there is also a decrease in Rb with GST treatment
alone The Rb antibody used detects total Rb levels in the
cell, therefore we could not assume a loss of phosphoryla-
tion due to the inhibitory effect of p16INK4A on cdk4/6. A
recent paper has addressed the literature-wide discrepan-
cies of RB dephosphorylation vs. degradation in response
to drug treatment or cell senescence in various cell types
[51]. It is possible that the increased amount of p16INK4A
present in these cells has induced a proteasomal degrada-
tion of Rb that has not otherwise been characterized in T
cells. The cell line panel in Figure 4D was also screened
for the presence of endogenous levels of Rb in these cell
lines, and interestingly there is a high degree of variabil-
ity. The T cell lines CEM, Jurkat, and the HIV-1 infected
J1.1 have the highest endogenous levels of Rb. Interest-
ingly, the monocytic cell lines U937 and the HIV-1
infected U1 have the lowest amount of Rb present, with
almost completely undetectable levels in HIV-1 infected
U1 cells. The variability supports the discrepancies seenVan Duyne et al. AIDS Research and Therapy 2010, 7:21
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Page 9 of 17
in the literature about hypo-, hyper-phosphorylation of
Rb, as well as depletion or degradation of Rb during cell
cycle or cellular responses.
Purified GST-p16 is found intracellularly in Jurkat, J1.1, 
U937, and U1 after treatment
In order to confirm that the effects seen by GST and
GST-p16INK4A  treatment in Figure 4A, B, and C, we
checked to ensure that the purified proteins are actually
entering the cell. Jurkat, J1.1, U937, and U1 cell lines were
treated with an excess (2.5 μg) of GST or GST-p16 (Figure
4E). At 48 hours post treatment, the cells were harvested,
washed extensively, lysed, and incubated with Glutathi-
one-Sepharose beads overnight. The Glutathione-Sep-
harose beads were washed extensively to remove any
non-specific proteins with buffers containing salts and
detergents. The bound proteins were subjected to West-
ern blot for the presence of p16INK4A as shown in Figure
4E. Jurkat whole cell extract served as the positive control
(lanes1 in both blots) and a higher molecular weight band
corresponding to GST-p16INK4a was observed in the GST-
p16INK4A pulldown lanes for each of the cell lines (lanes 4
and 7 in both blots). The lack of detection in the
untreated cell lysate incubated with beads alone indicates
that the protein detected in lanes 5 and 8 are specifically
the GST-bound proteins. These studies confirm that the
GST proteins are indeed entering the cells when incu-
bated in the extracellular environment.
Fascaplysin treatment mimics the exogenous p16INK4A 
treatment
In order to confirm that the cellular effects shown in Fig-
ure 4 are specific to the natural biological activity of
p16INK4A as a cdk4/6/Cyclin D inhibitor, we attempted to
mimic these studies with the small molecule compound
inhibitor Fascaplysin. Fascaplysin (FASC) is a naturally
derived molecule isolated from a marine sponge which
specifically inhibits the interaction between cdk4/Cyclin
D at an IC50 of approximately 0.35 μM, and to a lesser
extent cdk6/Cyclin D by binding the ATP pocket of cdk4,
resulting in cell cycle arrest at G1/S [52,53]. Again, we
treated latently infected HIV-1 cell lines (J1.1 and U1)
with three concentrations of FASC (100 nM, 500 nM, and
1 μM) and collected supernatants at 24, 48, and 72 hours
post treatment. The RT activity of both J1.1 and U1 cells
in the presence of FASC decreased over time with
increasing concentration of the drug. This indicates that
the presence of a general cdk4/Cyclin D inhibitor is able
Figure 2 Two-dimensional gel electrophoresis of pooled patient samples. Post sample depletion, six 2D gels (IPG Strip pH 3-10, 4-20% SDS-
PAGE) were run in tandem to separate the low and high abundance protein fractions of pooled patient serum samples in tandem. Gels a, b, and c are 
representative of LTNP, HAART, and Negative low abundance patient samples respectively. Gels d, e, and f are representative of LTNP, HAART, and 
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to decrease viral production in the same manner as exog-
enous p16INK4A. Additionally, we performed an MTT
assay to screen for the percentage of cells viable after Fas-
caplysin treatment. Figure 5B depicts % viability of Jurkat,
J1.1, U937, and U1cells treated with three concentrations
of FASC (100 nM, 500 nM, and 1 μM) after 48 hours.
Correlating with the viability assay presented in Figure
4B, approximately 50% of Jurkat cells were killed due to
additional cdk4/Cyclin D inhibition by 1 μM of FASC
treatment. None of the other cell lines exhibit appreciable
cell death which indicates that the drug treatment itself is
not toxic to the cells. In Figure 5C, we investigate the lev-
els of Rb present in Jurkat cells alone (lane 1) compared to
Jurkat cells that have been treated with three concentra-
tions of FASC (lanes 3, 4, and 5). Again, correlating with
our exogenous p16INK4A treatment data in Figure 4, we
observed a decrease in total cellular Rb levels at the high-
est concentration of FASC. This set of data confirms that
the cellular effects we observed with exogenous p16INK4A
may be due to the specific cdk inhibitory activity of this
molecule. It is interesting to note that these effects are
seen with simple protein treatment of the cells with a
purified molecule which may not have efficient entry as
compared to transfection or drug treatment. This sug-
gests that p16INK4A in the serum may be able to enter and
exit lymphocytes and exhibit its inhibitory effects during
an HIV-1 infection.
Fascaplysin treatment increases apoptosis in Jurkat cells 
and arrests latently infected J1.1 cells at G1/S in vitro
We previously showed that both p16INK4A and Fascaplysin
treatment results in a loss of cellular viability in Jurkat
cells as well as a decrease in viral production in infected
J1.1 and U1 cells. We were interested to detect the cell
cycle pattern of Jurkat, J1.1, U937, and U1 in response to
Fascaplysin treatment. Cells were treated with three con-
centrations of FASC (100 nM, 500 nM, 1 μM) and were
collected after 48 hours. Cells were fixed and stained with
Propidium Iodide and cell cycle analyzed using a FacsCal-
ibur Flow Cytometer. In Figure 6A-D, we compare the
population of cells in each stage of the cell cycle at the
three concentrations of FASC in Jurkat, J1.1, U937, and
U1 cells, as compared to the DMSO control. At the high-
est concentration of FASC, we observe an increase in the
apoptotic peak in Jurkat cells alone. This correlates with
the cellular viability data in p16INK4A and FASC treated
cells. Interestingly, we observed an arrest of cells at G1 in
the all of the other treated cell lines. These cell lines do
not contain endogenous levels of p16INK4A, therefore in
Figure 3 Western blot confirmation of MALDI-TOF identified serum proteins. A) Western blots were performed against pooled low (L) and high 
(H) abundance protein fractions for negative (lanes 2, 3), LTNP (lanes 4, 5), and HAART (lanes 6, 7) patients. Antibodies specific to cdk4, p16INK4A, 
PCTAIRE, HP1α, and HP1γ were used. B) Western blots were performed against individual patient samples 1-6, low and high abundant LTNPs. Anti-
bodies specific to p16INK4A and cdk4 were used. 293T, the pooled low abundance LTNP samples "A," and the pooled high abundance LTNP samples 
"D" were used as controls. C) Immunoprecipitation of p16INK4A from the individual low abundant LTNP patient samples, followed by a western blot 
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the presence of an additional cdk4/6/Cyclin D inhibitor,
we observed the normal G1/S arrest effect. There were
no major appreciable differences in cell cycle in the FASC
treated U937 and U1, however, looking at the protein
profile of endogenously expressed p16INK4A and Rb, it is
not surprising that these monocytic cell lines would
exhibit a different inhibitory pathway. Taken together, the
cell cycle data shown in Figure 6, supports the overall
notion of cdk4/6/Cyclin D inhibitory effect by p16INK4A
and Fascaplysin.
Discussion
The global proteomic analysis of serum proteins is not
without its challenges; however the presence or absence
of proteins in such bodily fluids of patients is often the
most accurate reflection of cellular leakage or secretion of
proteins in response to a disease state. Unfortunately, the
classical serum proteome contains a large concentration
of high abundance proteins that mask the individual pro-
teins that are unique to a particular phenotype. The iden-
tification of such low abundance serum proteins is
attractive as a method of early detection of a disease state
or a response to infection. Here, we demonstrate that the
detection of unique proteins in the serum of HIV-1
infected long-term non-progressors may be indicative of
a natural "immunity" to the progression of HIV-1 infec-
tion. Specifically, we have identified p16INK4A, a cdk4/6
inhibitor, as preferentially present in pooled serum of
HIV-1 LTNP patients, as opposed to HIV-1 infected indi-
viduals responding to HAART treatment.
P16INK4A  i s  a  m e m b e r  o f  t h e  I N K 4 / A R F  f a m i l y  o f
endogenous cdki's that serve to regulate cell cycle pro-
gression through the inhibition of specific cdk/Cyclin
interactions. P16INK4A is a critical member of the Rb/p16
tumor-suppressor pathway which inhibits the activation
of cdk4/6, preventing the progression through the cell
cycle. This tumor-suppressive pathway is mutated in
close to 100% of human cancers and specific loss-of-func-
tion mutations are found within the Rb  gene or the
CDKN2A gene encoding p16INK4A [54]. In addition to the
direct inactivation of these two proteins, cancer cells also
override this regulatory pathway by overexpressing cdk/
Cyclins as well as inducing the endogenous loss of expres-
sion of other cdk inhibitors. The loss of p16INK4A results
in the constitutive activation of cdk4/6 as well as pRb
hyperphosphorylation, therefore bypassing the anti-
oncogenic senescence induced by this cdk inhibitor. In
addition to necessitating an oncogenic state, the regula-
tion and manipulation of cellular cdks and Cyclins is also
critical for an active HIV-1 viral infection and occurs
mainly through the HIV-1 transactivator Tat. Tat inter-
acts with the cdk2/Cyclin E complex to phosphorylate
cdk7 and assist in the phosphorylation of the C-terminal
Domain (CTD) of RNA Pol II at the viral LTR (long-ter-
minal repeat) to promote viral transcription [55-57].
Cdk2 is also involved in the direct phosphorylation of Tat
at both serine 16 and 46, which are critical for efficient
Tat activity [56,57]. HIV-1 transactivation is also heavily
dependent on the recruitment of the cdk9/Cyclin T1
complex to the viral TAR element where it also assists in
the phosphorylation of the CTD of RNA Pol II as well as
an autophosphorylation event which is important for the
localization to the nucleus [58]. Taking into consideration
the recruitment of cellular kinases for HIV-1 transcrip-
tion, it is not surprising that pharmacological cdk inhibi-
tors have been developed (analogous to endogenous
cdki's) as a template to specifically inhibit these kinases.
Therefore, the presence of the cdk inhibitor p16INK4A in
LTNP serum is suggestive of an existing defense mecha-
nism in these patients that imparts a predisposition to a
lack of HIV-1 disease progression.
The development of pharmacological cdki's and pep-
tide mimetics is a commonly used approach for both can-
cer and viral therapeutics. For instance, p16INK4A peptides
have previously been developed, which, when conjugated
to localization proteins/peptides, were able to block cell
cycle progression in breast cancer and colon cancer cell
lines in vitro as well as reduce tumor size in an in vivo
mouse model of pancreatic cancer [59-61]. These pep-
tides have also been used for intracellular delivery to leu-
kemia and lymphoma derived cells [59,62]. These studies
have demonstrated the ability of cdki-derived peptides to
be used for both direct cell cycle arrest and the treatment
of metastatic cancers. This type of therapy is an appropri-
ate approach to cancerous states where the oncogenic
mutation results in a loss of function or expression of the
p16INK4A protein. Here, we show that p16INK4A is only
endogenously expressed in the Jurkat T-cell line and addi-
tional treatment of Jurkat cells with exogenous p16INK4A
results in a decrease in cellular viability. All additional
uninfected and infected cell lines used in this study did
not express endogenous levels of p16INK4A, suggesting
that a loss of function or expression may be present in
these particular cell types. More importantly, the treat-
ment of stably infected HIV-1 cell lines, J1.1 and U1, with
exogenous p16INK4A resulted in a decrease in viral replica-
tion with a minimal decrease in cellular viability, suggest-
ing that the presence of p16INK4A in the context of an in
vitro HIV-1 infection may mimic an in vivo infection in a
LTNP patient. The same dosage of p16 INK4A needed for a
decrease in viral replication in infected cells is not toxic
to uninfected cells, with the exception of Jurkat cells,
indicating that there may be a threshold for which the
effect of this cdk inhibitor begins to harm the cell and
potentially induce cell cycle arrest and apoptosis.Van Duyne et al. AIDS Research and Therapy 2010, 7:21
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In this study we also chose to reinforce the p16INK4A-
induced cdki effects seen on cellular viability and viral
replication with a known cdk4/6/Cyclin D inhibitor, Fas-
caplysin. We show that treatment of Jurkat cells with this
inhibitor also results in a decrease in cellular viability,
consistent with the effect seen by treatment with endoge-
nous p16INK4A. Additionally, the treatment of both stably
infected HIV-1 cell lines, J1.1 and U1, with Fascaplysin
resulted in a decrease in viral replication with a minimal
decrease in cellular viability. The correlation of this phar-
macological cdki inhibitor data with the functional-cdki
p16INK4A data suggests that the preferential inhibition of
the cdk4/6/Cyclin D interaction by LTNPs may contrib-
ute to this phenotype.
The high and low abundance fractions analyzed for
each of the three patient types were a pooled representa-
tion of six individual patient samples that almost cer-
tainly have inherent variability. Indeed, when assaying for
p16INK4A in high and low abundance serum fractions for
each individual LTNP patient, p16INK4A was present in
only a subset of the patients analyzed. This indicates that
although p16INK4A may serve as a unique serum protein
indicating a LTNP HIV-1 infected status, individual per-
son-to-person changes will alter the serum proteome
profile and needs to be taken into consideration. Differ-
ences in expression of p16INK4A can be due to either a host
cellular response to the infection or from an influence of
the infection itself. Two different scenarios need to be
Figure 4 Viral Replication and Cell Viability assays in the presence of exogenous p16INK4A treatment. A) J1.1 and U1 latently infected HIV-1 cell 
lines were treated with GST or GST-p16INK4A (0.1 μg or 0.5 μg). Cell culture supernatants were collected at 48 hours post treatment and assayed for 
reverse transcriptase (RT) activity measured in cpm. B) CEM, Jurkat, H9, and U937 uninfected cell lines were treated with GST or GST-p16INK4A (0.1 μg 
or 0.5 μg). Fourty-eight hours post treatment, the cells were measured for viability with MTT reagent. C) Jurkat uninfected T cells were treated with an 
excess (2.5 μg) of GST or GST-p16INK4A. Cells were collected at 48 hours post treatment and western blotted for the presence of Rb and Actin. D) CEM, 
Jurkat, H9, and U937 uninfected cell lines, as well as, J1.1 and U1 latently infected HIV-1 cell lines were assayed for the presence of endogenous levels 
of p16INK4A, cdk4, and Rb. One hundred micrograms of whole cell extract from each cell line was probed with antibodies against p16INK4A, cdk4, Rb, 
and Actin using Western blots. E) Uninfected/Infected cell line pairs Jurkat/J1.1 and U937/U1 were treated with GST or GST-p16INK4A (0.5 μg) to test for 
entry of GST-p16 into the cells. Cells were collected at 48 hours post treatment, washed, lysed, and incubated with Glutathione-Sepharose beads over-
night. Beads were washed extensively, and probed for the presence of GST-p16INK4A by western blot against p16INK4A. Arrows indicate the endoge-
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considered when examining the potential importance of
this protein in defining a viral disease state such as a
LTNP patient; the effect on the host and the effect on the
virus.
Finally, many complicating factors can contribute to the
altered state of proteins present in the serum, not the
least of which is the length of time in which the patient
has been infected, age, gender, coinfections, and other
preexisting conditions such as cancer or metabolic dis-
eases. Therefore, it is important to take into consider-
ation some of these factors when applying global
proteomic analyses to HIV-1 patient derived samples.
Materials and methods
Cell Culture and Protein Reagents
293T endothelial kidney cell line was harvested for whole
cell extract and used as a positive control. 293Ts were
grown in Dulbecco's modified Eagle's medium (DMEM)
containing 10% FBS, 1% L-glutamine, and 1% streptomy-
cin/penicillin (Quality Biological). Latently infected HIV-
1 cell lines J1.1 (T-cells) and U1 (monocytes) were used
for RT assays and whole cell extracts were obtained for
Western blots. Uninfected CEM, Jurkat, and H9 cell lines
(T-cells) and uninfected U937 cell line (monocytes) were
u s e d  f o r  v i a b i l i t y  a s s a y s  a n d  w h o l e  c e l l  e x t r a c t s  w e r e
obtained for Western blots. Uninfected cells were grown
in RPMI-1640 media containing 10% FBS, 1% L-glu-
tamine, and 1% streptomycin/penicillin (Quality Biologi-
cal). All cells were incubated at 37°C and 5% CO2. GST-
p16INK4A was a generous gift from Dr. Ming-Daw Tsai,
Institute of Biological Chemistry, Academia Sinica, Nan-
kang, Taipei, Taiwan
Serum Samples and Serum Depletion
Eighteen subject serum samples (6 LTNP, 6 HIV infected
subjects receiving HAART therapy, and 6 uninfected
individuals) were obtained through Washington DC site
of the Women's Interagency HIV Study (WIHS) (Table 1).
WIHS is an NIH multicenter study of the natural history
of HIV-1 infection in women [29]. LTNPs were defined by
WIHS as being HIV Infected, but disease free for at least
five years, a CD4 count of greater than 500 at all visits,
and no history of anti-retroviral therapy. Serum samples
were subjected to depletion of the 12 most abundant
serum proteins using the ProteomeLab IgY-12 High
Capacity Spin Column Proteome Partitioning kit from
Figure 5 Viral Replication and Cell Viability assays in the presence of the cdk4/6/Cyclin D inhibitor Fascaplysin. A) J1.1 and U1 latently infect-
ed HIV-1 cell lines were treated with Fascaplysin (100 nM, 500 nM, or 1 μM). Cell culture supernatants were collected at 48 hours post treatment and 
assayed for reverse transcriptase (RT) activity measured in cpm. DMSO treatment served as a negative control. B) Jurkat, J1.1, U937, and U1 cell lines 
were treated with Fascaplysin (100 nM, 500 nM, or 1 μM). Fourty-eight hours post treatment, the cells were measured for viability with MTT reagent. 
DMSO treatment served as a negative control. C) Jurkat uninfected T cells were treated with Fascaplysin (100 nM, 500 nM, or 1 μM). Cells were collected 
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Phenomenex (Torrance, CA). This spin column consists
of anti-human serum albumin, anti-IgG, anti-fibrinogen,
anti-transferrin, anti-IgA, anti-IgM, anti-HDL (anti-apo
A-I and anti-apo A-II), anti-haptoglobin, anti-α1-antit-
rypsin, anti-α1-acid glycoprotein and anti-α2-macroglob-
ulin conjugated to polymeric microbeads. Twenty
microliters of each serum sample was diluted 1:25 in dilu-
tion buffer and ran over the spin column. Low abundant
proteins were collected in the flowthrough and subse-
quent high abundant, bound proteins were retained and
eluted with a low pH stripping buffer. Protein concentra-
tions of both low and high abundant fractions were calcu-
lated and pooled as indicated.
2D-Gel Electrophoresis (2DGE) and MALDI-TOF MS
Five hundred micrograms of pooled LTNP, HAART, and
Negative patient samples for both Low and High abun-
dance fractions were subjected to isoelectric focusing on
an IPG strip, pH 3.0-10.0 and further subjected to SDS-
PAGE on a 4-20% Criterion Tris-Glycine gel. The gels
were stained with Coomassie Blue and protein spots of
interest were excised. Spots were vortexed, washed, and
equilibrated in 25 mM NH4HCO3, broken into smaller
pieces, and vortexed and washed 3X with 50% ACN/25
mM NH4HCO3 to remove the Coomassie from the gel.
Gel pieces were vortexed and washed with 100% ACN to
dehydrate the gel pieces. Gel pieces were re-swelled with
up to 200 ng of trypsin (in enough volume to cover the
gel) and incubated on ice for 30 min. Residual trypsin was
removed, 20 μl of 25 mM NH4HCO3 or enough to cover
the gel was added to the gel pieces and the reactions were
incubated overnight at 37°C. Peptides were extracted
with 1X dH2O wash with brief vortexing and sonication,
followed by 3X washes with 60% ACN/5% TFA. Extracted
peptides were pooled together and a SpeedVac was uti-
lized to reduce the volume to approximately 10 μl.
Twenty microliters of 0.1% TFA was added to each tube
and peptides were desalted using C18 ZipTips (Millipore)
according to manufacturer's instructions. Peptides were
spotted on MALDI sample plate 1:1 with α-cyano-4-
hydroxy cinnamic acid (CHCA) matrix solution: 10 mg
CHCA, 500 μl 100% ACN, 500 μl 0.1% TFA. Positive con-
trol calibration peptide solution of Bradykinin, Angio-
tensin II, P14R, and ACTH was spotted along with
negative control empty gel slice. Mass peaks obtained
were entered into Mascot http://www.matrix-
science.com/ and ProFound http://prowl.rockefeller.edu/
Figure 6 Fascaplysin induces apoptosis in Jurkat cells and G1/S arrest in latently infected J1.1 cells. Cell cycle analysis was performed on A) 
Jurkat, B) J1.1, C) U937, D) U1 that were treated with DMSO, 100 nM, 500 nM, or 1 μM Fascaplysin for 48 hours. Bars represent the percentage of gated 
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prowl-cgi/profound.exe databases for peptide mass fin-
gerprinting analysis.
Immunoprecipitations
Fifty microliters of pooled low abundance LTNP serum
sample "A" and individual low abundance LTNP serum
samples (1-6) were incubated with either α-IgG or α-
p16INK4A as indicated, volume was brought up to 500 μl
with TNE50  + 0.1% NP-40, rotating overnight at 4°C.
Extracts were incubated with 50 μl of a 30% slurry of Pro-
tein A + G Agarose beads (Calbiochem #IP05) for 2 hrs,
rotating, at 4°C. Beads were washed with indicated salt
washes (TNE600 + 0.1% NP-40, TNE300 + 0.1% NP-40,
TNE150 + 0.1% NP-40, or TNE50 + 0.1% NP-40), bound
proteins were removed from the beads with Laemmli buf-
fer and subjected to Western blots against p16INK4A.
Western Blots
Western blots were performed to validate proteins identi-
fied from depleted serum samples. Whole cell extracts
were obtained from cell culture pellets washed twice with
25 mL of phosphate buffered saline (PBS) with Ca2+ and
Mg2+ (Quality Biological) and centrifuged once more.
Cell pellets were resuspended in lysis buffer (50 mM Tris-
HCl, pH 7.5, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50
mM NaF, 0.2 mM Na3VO4, 1 mM DTT, one complete
protease cocktail tablet/50 mL) and incubated on ice for
20 min, with a gently vortexing every 5 min. Cell lysates
were transferred to eppendorf tubes and were centrifuged
at 10,000 rpm for 10 min. Supernatants were transferred
to a fresh tube where protein concentrations were deter-
mined using Bio-Rad protein assay (Bio-Rad, Hercules,
CA). Antibodies against cdk4 (sc-749), p16 (sc-467),
PCTAIRE (sc-174), Rb (sc-50), and Actin (sc-1615) were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Antibodies against HP1α and HP1γ were purchased
from Cell Signaling (Danvers, MA).
RT Assays
J1.1 and U1 cells (2 × 106) were treated with GST or GST-
p16 (0.1 or 0.5 μg) or Fascaplysin (100 nM, 500 nM, or 1
μM) and supernatants collected to test for the presence of
virus 48 hours post treatment. Jurkats were treated with
GST or GST-p16 (2.5 μg) for 48 hours prior to HIV-1
infection with the dual tropic strain 89.6. Supernatants
were collected at various time points post infection to
test for the presence of virus post treatment. Viral super-
natants (10 μl) were incubated in a 96-well plate with
reverse transcriptase (RT) reaction mixture containing
1X RT buffer (50 mM Tris-HCl, 1 mM DTT, 5 mM
MgCl2, 20 mM KCl), 0.1% Triton, poly(A) (1U/ml), pd(T)
(1U/ml), and [3H]TTP. The mixture was incubated over-
night at 37°C, and 5 μl of the reaction mix was spotted on
a DEAE Filtermat paper, washed four times with 5%
Na2HPO4, three times with water, and then dried com-
pletely. RT activity was measured in a Betaplate counter
(Wallac, Gaithersburg, MD).
MTT Assays
Five thousand cells were plated per well in a 96-well plate
and the next day cells were treated with GST or GST-p16
(0.1 or 0.5 μg) or Fascaplysin (100 nM, 500 nM, or 1 μM).
Forty-eight hours later, 10 μl MTT reagent (5 mg/ml) was
added to each well and plates incubated at 37°C for 3
hours. Next, 100 μl of DMSO was added to each well to
solubilize the violet crystals. The assay was read at 570
nM.
Cell cycle analysis
Cells were washed with PBS and fixed with 70% ethanol.
Following rehydration in PBS, cells were stained in PBS
containing 25 ug/ml propidium iodide (Sigma), 10 ug/ml
RNase A (Sigma) and 0.1% NP-40. Cells were analyzed on
a BD FacsCalibur flow cytometer. Cell cycle analysis and
measurement of apoptosis was performed using Cell-
Quest software. Aggregates and debris were excluded by
gating on the FL2W and FL2A parameters. Apoptosis was
considered to be the population of cells that were sub-G1.
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